An increased incidence of intraocular inflammation (IOI), including retinal vasculitis (RV) and retinal vascular occlusion (RO), was observed in patients who received BEOVU 6 mg with every 4 weeks (q4 week) dosing beyond the first 3 doses compared to aflibercept 2 mg every 4 weeks, in neovascular age-related macular degeneration (nAMD) in the MERLIN study. A causal link was observed between the treatment-emergent immune reaction against BEOVU and the BEOVU related “retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation” ( BASICHR0049 study).
RecallTracker